Therefore, our work identifies an epigenetically regulated pathway, HDAC3/C/EBP-α/B7x, which is responsible for HDAC inhibitor resistance in colorectal cancer, and also provides a promising therapeutic approach to reverse HDAC inhibitor resistance. The gene discussed is HDAC9; the disease is colorectal cancer.